Mesalazine/acetylcysteine

Drug Profile

Mesalazine/acetylcysteine

Alternative Names: Acetylcysteine/mesalamine; Acetylcysteine/mesalazine; ALTH12; Mesalamine/N-acetylcysteine; N-acetylcysteine/mesalamine; N-acetylcysteine/mesalazine

Latest Information Update: 03 Feb 2016

Price : $50

At a glance

  • Originator Altheus Therapeutics
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Free radical inhibitors; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Crohn's disease; Gastrointestinal disorders; Ulcerative colitis; Ulcerative proctitis

Most Recent Events

  • 23 Dec 2014 Phase-III clinical trials in Ulcerative colitis in USA (Rectal)
  • 09 Jan 2014 Altheus Therapeutics completes enrolment in the phase II ZA-201 trial for Ulcerative colitis in the US (NCT01586533,
  • 31 Dec 2013 Preclinical trials in Ulcerative proctitis in USA (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top